Profile: XenoPort, Inc. (XNPT.O)

XenoPort, Inc., incorporated on May 19, 1999, is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The Company focuses on development and commercialization efforts on potential treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, known in the United States by the trade name Solzira (gabapentin enacarbil) Extended Release Tablets, is being developed for the treatment of a number of CNS disorders. During the year ended December 31, 2008, XP13512 completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States. The Company’s portfolio of product candidates includes XP13512 for RLS, XP13512 for Neuropathic Pain, XP13512 for Migraine Prophylaxis, XP19986 for GERD, XP19986 for Spasticity, XP21279 for Parkinson’s Disease and XP21510 for the Treatment of Menorrhagia.

XP13512 for RLS

XP13512 is a Transported Prodrug of gabapentin. XP13512 is being evaluated for the treatment of restless legs syndrome (RLS) in a Phase III clinical program in the United States.

XP13512 for Neuropathic Pain

The Company has shown in a Phase IIa clinical trial that XP13512 improved clinical endpoints associated with PHN, a chronic type of neuropathic pain that can follow the resolution of shingles. Glaxo Group Limited (GSK) initiated a neuropathic pain clinical program that includes two Phase II clinical trials designed to evaluate the safety and efficacy of XP13512 in the management of PHN, as well as a Phase II clinical trial designed to evaluate the safety and efficacy of XP13512 in the treatment of painful diabetic neuropathy (PDN).

XP13512 for Migraine Prophylaxis

Migraine prophylaxis treatment is designed to reduce the frequency and severity of migraine attacks. GSK initiated a Phase II clinical trial designed to show the safety and efficacy of XP13512 in the prophylactic treatment of migraine headaches.

XP19986 for GERD

XP19986 is a Transported Prodrug of R-baclofen that the Company is developing for the treatment of GERD, which is a digestive system disorder caused primarily by transient relaxations of the lower esophageal sphincter. It completed a Phase IIa clinical trial indicating that single doses of XP19986 were well tolerated and produced statistically significant reductions in the number of reflux episodes in patients with gastroesophageal reflux disease.

XP19986 for Spasticity

Racemic baclofen, which contains both R-baclofen and S-baclofen, is approved in the United States for the treatment of spasticity resulting from multiple sclerosis, spinal cord injury and other spinal cord diseases. The Company was conducting a Phase II clinical trial of XP19986 in spinal cord injury patients with spasticity during 2008.

XP19986 for Acute Back Spasms

The Company was evaluating XP19986 as a potential treatment for the relief of discomfort from painful musculoskeletal conditions associated with acute back spasms during 2008. It initiated a Phase II clinical trial of XP19986 in patients with acute back spasms of neuromuscular origin in December 2008.

XP21279 for Parkinson’s Disease

XP21279 is a Transported Prodrug of levodopa, or L-Dopa. In February 2009, the Company announced positive results from a second Phase I clinical trial with two different sustained-release formulations of XP21279.

XP21510 for the Treatment of Menorrhagia

XP21510 is a Transported Prodrug of tranexamic acid. The Company licenses Xanodyne exclusive rights to develop and commercialize XP21510 in the United States, including for the potential treatment of women diagnosed with menorrhagia.

The Company competes with Eli Lilly, Boehringer Ingelheim, Pfizer, GSK, UCB group, Johnson & Johnson, Abbott, Depomed, Inc., AstraZeneca, Takeda Pharmaceutical Company Limited, Wyeth, Eisai/Johnson & Johnson, Cephalon, Inc., Meda Pharmaceuticals, Inc. and King Pharmaceuticals, Inc.